Global Point-of-Care Glucose Testing Market 2024–2033

Reports Description

As per the current market research conducted by the CMI Team, the global Point-of-Care Glucose Testing Market is expected to record a CAGR of 4.5% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 3,670.9 Million. By 2033, the valuation is anticipated to reach USD 5,455.3 Million.

The Point-of-Care Glucose Testing Market involves the production and distribution of devices and systems for measuring blood glucose levels outside traditional laboratory settings, providing real-time results for diabetes management. Key components include blood glucose meters, continuous glucose monitoring systems, and associated consumables like testing strips and lancets.

This market serves healthcare facilities, home care settings, and diagnostic laboratories, driven by factors such as the increasing prevalence of diabetes, technological advancements in glucose monitoring devices, and the shift towards patient-centered care. Point-of-care glucose testing enables timely intervention, personalized treatment plans, and improved patient outcomes in diabetes management.

Point-of-Care Glucose Testing Market – Significant Growth Factors

The Point-of-Care Glucose Testing Market presents significant growth opportunities due to several factors:

• Rising Diabetes Prevalence: The increasing incidence of diabetes globally is a significant driver, necessitating regular blood glucose monitoring and driving demand for point-of-care testing solutions.

• Technological Advancements: Ongoing innovations in glucose monitoring technology, such as continuous glucose monitoring (CGM) systems and minimally invasive devices, enhance accuracy and convenience, driving market growth.

• Patient-Centric Care: The shift towards patient-centered healthcare models emphasizes self-monitoring and personalized treatment plans, increasing the demand for point-of-care testing devices for diabetes management.

• Regulatory Support and Reimbursement Policies: Favorable regulatory environments and reimbursement policies for point-of-care testing encourage healthcare providers to adopt these devices, driving market expansion.

• Expansion in Emerging Markets: Penetrating emerging markets with growing healthcare infrastructure presents opportunities for market growth, as rising disposable incomes and increasing awareness of diabetes management drive demand for point-of-care testing solutions.

• Integration with Digital Health Platforms: Leveraging digital health platforms for data management, telemedicine, and remote patient monitoring presents opportunities for market players to enhance the value proposition of point-of-care glucose testing devices and services, catering to evolving healthcare needs.

Point-of-Care Glucose Testing Market – Mergers and Acquisitions

The Point-of-Care Glucose Testing Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Point-of-Care Glucose Testing Market include:

• In 2024, Trinity Biotech (TRIB) completed the acquisition of biosensor and Continuous Glucose Monitoring (CGM) assets from Waveform Technologies for $12.5 million in cash and 9 million American Depositary Shares (ADSs). This strategic move enhances Trinity Biotech’s position in diabetes care and biosensor market innovation.

• In 2023, the Canadian government approved Dexcom’s next-generation Dexcom G7 Continuous Glucose Monitoring System for type-1 diabetes patients in Canada. This advanced system offers improved glucose monitoring capabilities, empowering patients with real-time data for better diabetes management.

• In 2022, Roche introduced the cobas pulse system, a pioneering professional blood glucose management solution featuring mobile digital health capabilities. This innovative system aims to enhance patient care by providing real-time glucose monitoring and data accessibility for healthcare professionals.

These mergers and acquisitions helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Point-of-Care Glucose Testing Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Point-of-Care Glucose Testing Market	Embolic Protection Device Market	Serological Testing Market
CAGR 4.5% (Approx)	CAGR 7.6% (Approx)	CAGR 6.70% (Approx)
USD 5,455.3 Million by 2033	USD 3,562.2 Million by 2033	USD 8,100 Million by 2033

Point-of-Care Glucose Testing Market – Significant Threats

The Point-of-Care Glucose Testing Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

• Regulatory Compliance Challenges: Stringent regulatory requirements and standards for medical devices pose challenges for manufacturers in terms of compliance, leading to delays in product approvals and market entry.

• Competition from Alternative Technologies: Increasing competition from alternative glucose monitoring technologies, such as continuous glucose monitoring (CGM) systems and implantable sensors, threatens the market share of traditional point-of-care glucose testing devices.

• Price Pressure and Cost Containment Measures: Price pressure from healthcare providers and payers, coupled with cost containment measures, may lead to downward pricing pressure on point-of-care glucose testing devices, affecting manufacturers’ profit margins.

• Limited Reimbursement Coverage: Limited or inconsistent reimbursement coverage for point-of-care glucose testing devices and related consumables in certain regions may hinder market growth, especially in low-income or underinsured populations.

• Technological Obsolescence: Rapid technological advancements and the introduction of new glucose monitoring technologies may render existing point-of-care testing devices obsolete, leading to product obsolescence and loss of market relevance for manufacturers.

Category-Wise Insights

By Product:

• Accu Check Aviva Meter: The Accu-Chek Aviva Meter is a blood glucose monitoring device known for its accuracy and ease of use, catering to individuals with diabetes for self-monitoring of blood glucose levels. Trends include advancements in data connectivity, allowing seamless integration with digital health platforms for remote monitoring and data analysis, and enhancing patient engagement and healthcare outcomes.

• Onetouch Verio Flex: The Onetouch Verio Flex is a compact and user-friendly blood glucose monitoring system designed for convenient self-monitoring by individuals with diabetes. Trends include the integration of Bluetooth technology, enabling wireless data transmission to smartphones and tablets for real-time tracking and analysis. Additionally, the focus is on enhancing data visualization and interpretation through user-friendly mobile applications.

• i-STAT: The i-STAT system is a portable point-of-care blood glucose testing device commonly used in clinical settings for rapid and accurate glucose measurements. Trends include the integration of multi-analyte testing capabilities, allowing simultaneous measurement of glucose and other biomarkers, streamlining clinical workflows and improving diagnostic efficiency.

• Bayer CONTOUR Blood Glucose Monitoring System: The Bayer CONTOUR Blood Glucose Monitoring System offers reliable and accurate glucose measurements for individuals managing diabetes. Trends include the development of next-generation devices with enhanced accuracy, faster testing times, and improved usability features such as larger display screens and intuitive user interfaces, enhancing the user experience and adherence to self-monitoring routines.

• Freestyle Lite: The Freestyle Lite blood glucose monitoring system provides users with a convenient and reliable solution for monitoring blood glucose levels. Trends include the integration of advanced sensor technology, allowing for smaller blood sample sizes and faster testing times, enhancing user convenience and reducing discomfort associated with blood glucose testing.

• True Metrix: The True Metrix blood glucose monitoring system offers users accurate and reliable glucose measurement in a compact and user-friendly device. Trends include the development of smart meters with wireless connectivity features, enabling seamless data transfer to mobile applications and cloud-based platforms for remote monitoring and data analysis, enhancing patient engagement and healthcare outcomes.

• Accu-Chek Inform II: The Accu-Chek Inform II is a point-of-care blood glucose testing system designed for use in clinical settings, offering rapid and accurate glucose measurements for critically ill patients. Trends include advancements in connectivity and interoperability, allowing seamless integration with hospital information systems for real-time data transmission and electronic medical record documentation, improving clinical workflow efficiency and patient care.

• StatStrip: The StatStrip blood glucose monitoring system is widely used in healthcare facilities for accurate and efficient glucose testing at the point of care. Trends include innovations in quality control and assurance measures, ensuring the accuracy and reliability of test results, and compliance with regulatory standards, enhancing patient safety and confidence in testing outcomes.

• Others: Other segments in the Point-of-Care Glucose Testing Market encompass a diverse range of blood glucose monitoring devices, including emerging technologies such as continuous glucose monitoring (CGM) systems, implantable sensors, and non-invasive glucose monitoring devices. Trends focus on improving accuracy, usability, and connectivity features, as well as enhancing data integration and interoperability with digital health platforms, driving innovation and market growth in the diabetes management landscape.

By Technology

• Glucose Oxidase Based Testing: Glucose oxidase-based testing relies on the enzyme glucose oxidase to catalyze the oxidation of glucose, producing hydrogen peroxide. This reaction is measured to determine blood glucose levels. Trends include the development of compact glucometers with improved accuracy and connectivity features, enabling seamless integration with digital health platforms for real-time data monitoring and analysis.

• Glucose Dehydrogenase Based Testing: Glucose dehydrogenase-based testing utilizes the enzyme glucose dehydrogenase to catalyze the oxidation of glucose, generating electrons. The flow of electrons is measured to determine blood glucose levels. Trends include the introduction of minimally invasive testing devices and continuous glucose monitoring systems, providing real-time glucose monitoring and enhancing patient convenience and compliance.

• Others: Other technologies in the Point-of-Care Glucose Testing Market include electrochemical biosensors, optical sensors, and non-enzymatic methods. Trends in this segment focus on improving sensor accuracy, miniaturization of devices for portability, and the development of integrated systems for comprehensive glucose monitoring and data management, catering to diverse patient needs and preferences.

By Application

• Type-1 Diabetes: Point-of-care glucose testing in Type-1 Diabetes involves regular monitoring of blood glucose levels to manage insulin therapy effectively. Trends include the adoption of continuous glucose monitoring (CGM) systems for real-time data, integration with insulin pumps for automated insulin delivery, and the development of closed-loop systems for improved glucose control, enhancing patient outcomes and quality of life.

• Type-2 Diabetes: In Type-2 Diabetes, point-of-care glucose testing aids in monitoring blood glucose levels to guide lifestyle modifications and medication management. Trends include the integration of digital health solutions for remote monitoring and telehealth consultations, the development of user-friendly glucose monitoring devices, and the emphasis on preventive healthcare strategies to mitigate the progression of the disease, promoting better disease management and patient adherence.

By End Users

• Hospitals and Clinics: Hospitals and clinics utilize point-of-care glucose testing devices for rapid and accurate blood glucose monitoring of patients, both in inpatient and outpatient settings. Key trends include the integration of glucose testing devices into electronic health record systems, the adoption of wireless connectivity for seamless data transfer, and the emphasis on quality assurance and regulatory compliance to ensure accurate test results.

• Home Care Settings: Point-of-care glucose testing devices are increasingly utilized in home care settings, enabling individuals with diabetes to monitor their blood glucose levels conveniently and regularly. Trends include the development of user-friendly devices with simplified operation and data management features, integration with telehealth platforms for remote monitoring, and emphasis on patient education and empowerment to facilitate self-management of diabetes.

• Others: Beyond hospitals, clinics, and home care settings, point-of-care glucose testing devices find applications in various settings such as pharmacies, schools, workplace wellness programs, and community health centers. Trends in this segment include the expansion of point-of-care testing services to non-traditional healthcare settings, the adoption of mobile health technologies for on-the-go testing, and collaboration with public health initiatives to promote diabetes screening and prevention.

Report Scope

Feature of the Report	Details
Market Size in 2024	USD 3,670.9 Million
Projected Market Size in 2033	USD 5,455.3 Million
Market Size in 2023	USD 3,512.8 Million
CAGR Growth Rate	4.5% CAGR
Base Year	2023
Forecast Period	2024-2033
Key Segment	By Product, Technology, Application, End Users and Region
Report Coverage	Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope	North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options	Request tailored purchasing options to fulfil your requirements for research.

Point-of-Care Glucose Testing Market – Regional Analysis

The Point-of-Care Glucose Testing Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

• North America: North America sees a trend towards increased adoption of advanced point-of-care glucose testing technologies, such as continuous glucose monitoring (CGM) systems, driven by a strong emphasis on patient-centered care and healthcare innovation. Additionally, there is a growing focus on integration with electronic health records (EHR) systems and telemedicine platforms to enhance data accessibility and remote patient monitoring capabilities, aligning with the region’s healthcare digitization efforts.

• Europe: In Europe, the trend towards sustainability and environmental responsibility influences the point-of-care glucose testing market. There is a growing demand for eco-friendly and recyclable materials in device manufacturing, driven by stringent regulatory standards and consumer preferences for sustainable healthcare solutions. Additionally, there is an increasing emphasis on interoperability and data sharing among healthcare providers to facilitate seamless patient care coordination across borders.

• Asia-Pacific: The Asia-Pacific region experiences a trend towards greater accessibility and affordability of point-of-care glucose testing devices, particularly in emerging economies. Manufacturers are focusing on developing cost-effective and user-friendly devices tailored to the needs of diverse patient populations. Additionally, there is a growing trend towards telehealth and mHealth solutions, leveraging mobile technologies to extend healthcare services to remote and underserved areas, driving market expansion.

• LAMEA (Latin America, Middle East, and Africa): In LAMEA, the trend towards market expansion is driven by initiatives to strengthen healthcare infrastructure and improve access to healthcare services. Governments and healthcare organizations are investing in point-of-care testing programs to address the burden of chronic diseases, including diabetes, in the region. There is also a growing trend towards public-private partnerships and collaborations to overcome resource constraints and enhance healthcare delivery capabilities.

Competitive Landscape – Point-of-Care Glucose Testing Market

The Point-of-Care Glucose Testing Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

• Abbott Laboratories
• Hoffmann-La Roche Ltd.
• Ascensia Diabetes Care Holdings AG
• Dexcom, Inc.
• Medtronic plc
• LifeScan, Inc. (A Johnson & Johnson Company)
• Becton, Dickinson and Company
• Acon Laboratories, Inc.
• Nova Biomedical Corporation
• ARKRAY, Inc.
• Trividia Health, Inc.
• PTS Diagnostics
• Nipro Diagnostics, Inc.
• Ypsomed Holding AG
• Sanofi S.A.
• Others

These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.

New players entering the point-of-care glucose testing market are leveraging innovation to establish their presence. Companies like iHealth Labs, One Drop, and AgaMatrix are introducing novel technologies, such as smartphone-connected glucometers and AI-driven data analytics, to differentiate themselves.

Meanwhile, key players dominating the market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Ascensia Diabetes Care Holdings AG. These industry giants maintain market leadership through extensive product portfolios, global distribution networks, and continuous R&D investments, ensuring superior product quality, reliability, and market reach.

The Point-of-Care Glucose Testing Market is segmented as follows:

By Product

• Accu Check Aviva Meter
• Onetouch Verio Flex
• i-STAT
• Bayer CONTOUR Blood Glucose Monitoring System
• Freestyle Lite
• True Metrix
• Accu-Chek Inform II
• StatStrip
• Others

By Technology

• Glucose Oxidase Based Testing
• Glucose Dehydrogenase Based Testing
• Others

By Application

• Type-1 Diabetes
• Type-2 Diabetes

By End Users

• Hospitals and Clinics
• Home Care Settings
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America